Accéder au contenu
Merck

Cimetidine: an anticancer drug?

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2011-02-19)
Martina Kubecova, Katarina Kolostova, Daniela Pinterova, Grzegorz Kacprzak, Vladimir Bobek
RÉSUMÉ

Cimetidine, H(2) receptor antagonists, is commonly prescribed for gastric and duodenal ulcer disease. Additionally, cimetidine has been shown to have anticancer effects. This review describes the mechanism of antitumor action of cimetidine including its ability to interfere with tumor cell adhesion, angiogenesis and proliferation; its effect on the immune system; as well as inhibition of postoperative immunosuppression. Its anticancer effect is also compared to that of the other H(2) receptor antagonists as well as outcomes of cimetidine in clinical studies in cancer patients.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Cimetidine
Supelco
Cimetidine, Pharmaceutical Secondary Standard; Certified Reference Material
Cimetidine, European Pharmacopoeia (EP) Reference Standard
Cimetidine for system suitability, European Pharmacopoeia (EP) Reference Standard
Cimetidine for peak identification, European Pharmacopoeia (EP) Reference Standard